Longitudinal Monitoring During Intermittent Fasting Protocols in Obese Adults

Launched by UNIVERSITY OF ZURICH · Mar 14, 2024

Keywords

ClinConnect Summary

The LIMITFOOD2 trial is studying how different types of intermittent fasting can affect the health of adults who are obese. Specifically, the trial will look at two fasting methods: modified alternate day fasting and time-restricted eating. Participants will be divided into three groups, with one group following the fasting methods and another group receiving general advice on weight loss. The goal is to see which approach, if any, helps improve health outcomes for people with obesity.

To join the study, participants need to be between 18 and 50 years old and have a body mass index (BMI) between 30 and 40, which means they are classified as obese. They should also have stable weight and not be taking certain medications that could interfere with the study results. Participants can expect to follow a specific eating plan depending on their assigned group and will be monitored throughout the trial. It’s important to know that people with certain health conditions or dietary restrictions won’t be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-50 years, both inclusive
• • Obese, BMI between 30 and 40 kg/m\^2 (obesity grade I or II), both inclusive
• • Non-smoker
• • Good knowledge of German or English language
• • Stable weight change (change \< +/- 3% current bodyweight) for 3 months prior to the study
• • HbA1c \< 6.5% without glucose lowering medication
• • LDL-cholesterol \< 4.6mmol/l without lipid lowering medication
• Exclusion Criteria:
• • Participants who have a fasting period of \> 12h per day on a regular basis and do not eat at least three main meals per day.
• • Current habitual use of dietary supplements (e.g., vitamins, minerals) and/or unwillingness to cease intake of dietary supplements.
• • Antibiotics intake during 3 months prior to the study due to possible interference with metabolic parameters
• • Food intolerances, allergies and sensitivities (severe food allergies) or dietary restrictions (e.g. vegan lifestyle)
• • Acute or chronic infections, malignant disease, renal, hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or psychiatric diseases, manifested atherosclerosis, or any other disease precluding participation in the study.
• • Diabetes
• • Known alcohol, substance or drug abuse, concomitant medication
• • More than four hours of physical exercise per week
• • Women who are pregnant, breast-feeding or aiming to become pregnant during course of the trial
• • Women and men on hormonal supplementation
• • Women with an irregular menstrual cycle according to the FIGO criteria
• • Therapy with antidepressants within the past 6 months
• • Regular therapy with acetylsalicyclic acid or current medication to regulate blood sugar, blood pressure or lipids
• • Participants likely to fail to comply with the study protocol
• • Participants who do not give informed consent